top of page
  • Facebook
  • Twitter
  • Instagram
Swainson Headshot_edited_edited.png

Jennifer Swainson, MD, FRCPC
Clinical Professor
Department of Psychiatry, University of Alberta

Psychopharmacology in Aging Women
Wednesday, February 10, 2027
3:45 PM - 4:45 PM

Jennifer N. Swainson, MD, FRCPC, DABOM is a Clinical Professor in the Department of Psychiatry at the University of Alberta and a psychiatrist at the Misericordia Hospital in Edmonton, Canada.

Clinically, Dr. Swainson specializes in the management of mood disorders and their common comorbidities, with particular expertise in treatment-resistant depression and bipolar depression. She has developed nationally recognized expertise in ketamine-based treatments, co-leading clinical programs to improve patient access through non-parenteral approaches, while advancing understanding of safety and abuse liability.

Dr. Swainson is a co-author of the Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Depression Treatment Guidelines, and a 2021 CANMAT statement on the use of Ketamine for Depression. She has an extensive record of peer-reviewed publications spanning numerous aspects on the use of ketamine, esketamine, and psychedelic treatments.

Dr. Swainson is actively involved in national and international psychopharmacology education and has contributed to the development of peer education programs in the areas of depression, bipolar disorder, ADHD, insomnia, metabolic health in psychiatric management, and women’s mental health.
She is also a dedicated teacher and research supervisor for trainees in psychiatry.

In addition to her psychiatric training, Dr. Swainson is a Diplomate of the American Board of Obesity Medicine, which informs another area of focus -- an integrated approach to mental illness with careful consideration of metabolic health. Her work emphasizes individualized, evidence-based care for complex populations, including aging women, where hormonal, metabolic, and physical health factors intersect.
 

Lecture Summary:

This presentation will examine how age-related physiological and medical changes influence psychotropic medication use in women across midlife and later life. The session will review considerations affecting medication selection, dosing, efficacy, and tolerability, while addressing the impact of medical comorbidities and changes in metabolic, cognitive, sexual, and sleep health. It will also explore practical strategies for initiating, switching, augmenting, and deprescribing medications to support individualized treatment decisions that balance effectiveness, tolerability, and long-term health.

​Goals and Learning Objectives:

  • Objective 1 : Identify key age-related factors to consider when prescribing psychotropic medication in women across midlife and later life.

  • Objective 2 : Integrate medical comorbidities into individualized psychopharmacological decision-making.

  • Objective 3 : Consider the balance between efficacy, tolerability, and long-term health when initiating, switching, augmenting, or deprescribing psychotropic medications in aging women.

 

Disclosures:

Advisory Board : AbbVie, Biogen, Eisai, Elvium, Idorsia, Lundbeck, Johnson and Johnson, Otsuka
Grant/Research Support : Canadian Institute for Health Research
Consultant : AbbVie, Biogen, Eisai, Idorsia, Lundbeck, Johnson and Johnson, Otsuka, College of Physicians and Surgeons of Alberta
Speakers' Bureau or Honoraria : AbbVie, Bausch, Biogen, Eisai, Elvium, Idorsia, Lundbeck, Johnson and Johnson, NovoNordisk, Otsuka

bottom of page